Best Biotechnology Stocks 2026

The major US-listed biotech stocks in 2026 include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Argenx (ARGX), and clinical-stage names like Crispr Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Beam Therapeutics (BEAM). Vertex and Regeneron have been the highest-quality large-cap operators.

Biotechnology companies develop therapeutics through biological methods — recombinant DNA, monoclonal antibodies, gene therapy, RNA, cell therapy. Traditional pharmaceutical companies focus on small-molecule chemistry, though most large pharma companies now have substantial biological capabilities. The categorisation has blurred — Eli Lilly, Novo Nordisk, AbbVie, and Bristol-Myers Squibb all have significant biological portfolios but are typically categorised as pharma. Vertex, Regeneron, Gilead, and Amgen are categorised as biotech despite being large and diversified.

Casgevy (Vertex/Crispr Therapeutics) was the first FDA-approved CRISPR-based therapy and demonstrated commercial viability of gene editing. Commercial uptake has been slow due to ex vivo manufacturing complexity, patient conditioning regimens, and reimbursement challenges at $2+ million per patient. In vivo gene editing from Beam Therapeutics, Intellia, and Verve Therapeutics offers simpler administration and broader addressable markets if proof-of-concept holds. The category remains high-risk for clinical-stage names but represents a fundamentally new therapeutic modality.

The Inflation Reduction Act of 2022 allows Medicare to negotiate prices on selected high-cost drugs after a market exclusivity period. The first negotiated prices took effect in 2026 and affect several major biotech products. Companies with concentrated franchises in negotiated drugs face material revenue and margin impacts. The Act also caps Medicare beneficiary out-of-pocket costs at $2,000 annually, which has affected certain specialty drug demand patterns. Long-term implications for biotech R&D investment economics remain debated.

Amgen, Gilead Sciences, and Regeneron all pay regular dividends. Amgen has the longest payout history among major biotechs and a yield often above the S&P 500 average. Vertex and clinical-stage biotechs typically do not pay dividends, prioritising R&D and selective M&A. Check the live data in the table for current yields and payout ratios.

Biotechnology carries acute clinical and regulatory risk. A single failed Phase 3 trial can permanently impair company value. FDA rejection of a lead asset can trigger 50%+ share declines. Clinical-stage biotechs without approved products are particularly volatile — cash position relative to burn rate is critical. Large-cap biotechs with diversified product portfolios (VRTX, REGN, GILD, AMGN) carry meaningfully less single-asset risk. Volatility in this group can be large.

Leqembi (Biogen/Eisai) and Kisunla (Lilly) are the first FDA-approved disease-modifying Alzheimer's therapies. Commercial uptake has been slower than initial bull-case expectations due to MRI monitoring requirements for ARIA side effects, infusion logistics, and Medicare reimbursement constraints. Subcutaneous formulations and earlier-intervention approvals are expected to expand the patient population over time. The long-term commercial opportunity remains substantial but near-term revenue ramps have disappointed.